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Abstract
Objective To investigate the utilization of antiepileptic
drugs (AEDs) in Dutch children and compare this with
guidelines on the treatment of epilepsy in children.
Method From the Dutch Interaction Database (IADB.nl)
we selected children aged 0–19 years who received at least
one prescription for an AED (ATC-code beginning with
N03A) between 1997 and 2005. We calculated cumulative
incidences and prevalences per 1000 children per year,
stratified by age-category, sex and type of AED, and the
total number of months each patient received at least one
prescription of AEDs, and we counted the number of
person-months and AEDs prescribed. For each AED,
proportions of person-months were calculated for mono-
and combination therapy. Kaplan-Meier survival analysis
was used to analyse the duration of AED use, stratified
by sex.
Results The overall prevalence of the prescription of AEDs
to children was constant at approximately 4.0 per 1000
children during the years of the study. The overall
cumulative incidence from 1997–2005 was 0.67 per 1000
children. When stratified by age category or sex, there were
no relevant differences in incidence or prevalence. Valproic
acid was the most frequently prescribed drug, followed by
carbamazepine and lamotrigine. In 20.3% of all person-
months, patients received combination therapy; of these,
34.2% received combination therapy for 3 person-months
or less. The older AEDs were prescribed more often as
monotherapy than combination therapy, in contrast with the
newer AEDs, for which the opposite was true. The 50%
survival probability (= time period when 50% of children
had stopped using AEDs) was around 2 years, with a
significantly lower discontinuation of treatment for girls
than boys (P = 0.04).
Conclusion The overall cumulative incidence of AEDs was
determined to be 0.67 per 1000 children, and the prevalence
4.0 per 1000 children. The most frequently prescribed drug
is valproic acid, followed by carbamazepine and lamotri-
gine. The prescribing of AEDs seems to be in conformity
with the overall recommendations of the guidelines on the
treatment of epilepsy in children.
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Introduction
Epilepsy is one of the most common neurological disorders.
Its incidence is highest during childhood, with a median
incidence for children aged 0–14 years of 0.822 per 1000
children [1]. It has also been estimated that 70% of all
epilepsy syndromes start between the age of 0 and 19 years
[2]. The vast majority of children with epilepsy receive
given antiepileptic drug (AED) therapy—for example, in
Sweden, 81.0% of epileptic children are treated with AEDs
[3]. However, even though many children suffer from
epilepsy and are treated AEDs, very little is known about
the prescribing and use of AEDs in children, especially on
the prescribing of AEDs in combination therapy and the
duration of use.
Many AEDs have been developed and registered over
the years. Table 1 shows the AEDs available on the Dutch
market in 2005 with their approval date and Anatomical
Therapeutic Chemical classification (ATC) code. The
approval given to these AEDs on these dates was not
subject to age restrictions that might be given in the
Supplementary Protection Certificates (SPCs), so some of
the AEDs may not even be licensed for children.
The Food and Drug Administration (FDA) approved a
number of AEDs for the treatment of indications other than
epilepsy, such as bipolar disorder, migraine prophylaxis,
mania and neuralgia.
Several guidelines for the treatment of epilepsy in
children have been published [2, 4], including a Dutch
guideline for (pediatric)neurologists and paediatricians in
the Netherlands [5]. These guidelines recommend that the
diagnosis of ‘epilepsy’ be limited to a specific seizure type
and/or epileptic syndrome in order to achieve the best
available treatment. The treatment recommendations in the
guideline are ordered by type of seizure of the epileptic
syndrome; however, the overall conclusion that can be
drawn from the guideline is that valproic acid is the most
effective drug—and therefore the drug of choice—for
most types of epilepsy, followed by carbamazepine and
lamotrigine.
We describe here the prescribing patterns of AEDs in
Dutch children with an emphasis on type of AED, mono-
versus combination therapy of AEDs and the duration of
use, and we compare these with guidelines on the treatment
of epilepsy in children.
Methods
Setting and study population
This study was performed with data extracted from the
InterAction database (www.IADB.nl), a prescription data-
base containing pharmacy dispensing data from pharmacies
located in the northern and eastern parts of the Netherlands
[6]. In the period from 1997 to 2005, the IADB.nl covered
a population of approximately 500,000 people. The size of
this population increased during the study period, but there
were no changes in age and gender distribution [7]. The
IADB includes all prescriptions, regardless of prescriber,
insurance or reimbursement status, with the exception of
over-the-counter (OTC) drugs and drugs dispensed during
hospitalization. In the Netherlands, people commonly
register with one pharmacy and obtain all of their
medication from that pharmacy; therefore, a complete
medication history of an individual is available in the
pharmacy dispensing records.
Children aged 0 to 19 years who from 1997 to 2005
received at least one prescription for an AED (ATC-code
N03A*; Table 1) were selected from the IADB.nl.
All AEDs available in the Netherlands were studied,
regardless of age restrictions and restrictions in approved
indication, because off-label prescription to children of
AEDs is possible. Diazepam and a number of other
benzodiazepines were not included in the study since they
are prescribed mainly for the treatment of prolonged
seizures and not for chronic treatment.
Although one might presume that these drugs are most
commonly prescribed to children for the treatment of
epilepsy, the specific disorder for which the AED was
prescribed was not known. Therefore, we classified the
probable indication based on the other prescriptions that the
Table 1 Information on antiepileptic drugs (AEDs) registered in the

















Fatty acid derivates Valproic acid 16–06–1971 N03AG01
Vigabatrina 28–09–1990 N03AG04







ATC-code, Anatomical Therapeutic Chemical classification code; NL,
the Netherlands
a New antiepileptic drugs (AEDs)
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child received. When a child received more than one
prescription for an antidepressant (ATC-code N06A*) or an
antipsychotic drug (ATC-code N05A*), we presumed that
the AEDs were prescribed for a bipolar disorder. When
propranolol or antimigraine drugs (ATC-code N02C*) were
prescribed, we presumed the indication was migraine.
When there were fewer than two prescriptions for one of
the above mentioned drugs, we presumed epilepsy to be the
indication for which the AED was prescribed.
Data analyses
Annual prevalences and cumulative incidences were calcu-
lated for all children and stratified by sex and age categories
of 5 years. Because of low cumulative incidences, the latter
are nearly equal to incidence density figures (number per
total person-years). Prevalences and cumulative incidences
were also stratified by individual AED (based on ATC-
code). We also stratified by type of AED, based on
approval date in the USA [8] (newly approved AEDs are
indicated in Table 1).
The cumulative incidences of AED prescriptions were
defined as the number of children who received initial
treatment with an AED, also divided by the total number of
children in the population and multiplied by 1000. Initial
treatment was defined as the first AED prescription in the
IADB.nl, when the child was in the database at least 6
months before the first AED was prescribed or aged 2 years
or younger when the first AED was prescribed. When a
child received two different AEDs at the date of the initial
treatment, both were counted. A child could only once be a
first time user, so when at a later time during treatment the
prescribed AED was changed or the treatment was resumed
after an AED-free period, the child was not counted again
as an incident user.
Annual prevalences were calculated by counting the
number of children receiving one or more prescriptions for
an AED, divided by the total number of children in the
population per age and sex group in the respective years,
and then multiplied by 1000.
For both the prevalences and cumulative incidences,
95% confidence intervals (CIs) were calculated using the
‘Score with CC’-method, because this method is very
suitable for small proportions [9]. When there were no
significant differences (P > 0.05) but a trend was suspected,
a Chi-square test for trend was conducted.
To investigate combination therapy, the prescriptions of
every child were divided into person-months. This was
done because pharmacotherapy can change several times
during 1 year, therefore counting only children or person-
years would result in a loss of data, while counting person-
months would preserve more of this information. For each
patient we calculated the total number of months they
received at least one prescription of AEDs and counted the
number of person-months. For every person-month, the
number of AEDs and the ATC-codes of the prescribed
AEDs were registered.
For every AED, we counted the number of person-
months in which the AED was given as monotherapy and
the number of person-months in which the AED was given
together with at least one other AED (combination therapy).
Using these values, we calculated the percentages of the
total number of person-months of all children per AED.
For the analyses of combination therapy, we removed
clonazepam from the data because this AED is usually not
prescribed for chronic treatment, but mainly for the acute
treatment of prolonged seizures. Since it was not known
when and how much clonazepam was used, person-months
could not be calculated.
Kaplan-Meier analyses were conducted to examine
the duration of use of all children and stratified by sex.
The start of the therapy was defined the same as for the
cumulative incidence rates. To determine the day on which
the therapy was ended, we calculated the number of days of
use for every prescription from the daily dosage and the
prescribed number of units (tablets, etc.). When there were
90 days or more between the last day of use of one
prescription and a subsequent prescription (if any), the
therapy was defined to be ended. The number of days
between the initial treatment and the last day of use before
the end was counted. When a child was in the database 90
days or less after the end of the treatment, the case was
defined as censored.
The results revealed that the data had a log-normal
distribution and many censored cases (50%). Consequently,
mean, median and CIs could not be calculated. To compare
two curves, we used the ‘Generalized accelerated failure
time’-model to determine significant (P < 0.05) differences.
This statistical analysis was conducted using R ver. 2.5.0
(R Foundation for Statistical Computing, Vienna, Austria).
Results
Overall utilization
From the IADB.nl we identified 1527 children [791 boys
(51.8%) and 736 girls (48.2%)] aged 0–19 years who had
received at least one AED prescription between 1997 and
2005, with a total of 182,201 prescriptions during this
period. All AEDs mentioned in Table 1 were prescribed,
except for zonisamide.
We estimated that AEDs had been prescribed for
epilepsy in at least 80% of these children, while approxi-
mately 10% had received the drugs for mood disorders and
5% for migraine.
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The total number of children in the population covered
by the IADB.nl is shown in Table 2, together with the
yearly cumulative incidences. Throughout the study period,
the cumulative incidence remained constant at around 0.67
per 1000 children. There were no significant differences
between boys and girls or between age categories (data not
shown).
Figure 1 shows the overall prevalence, which was
constant around 4.0 per 1000 children throughout the study
period. There were no significant differences both sexes or
between age-categories (data not shown).
Figure 1 also shows the prevalence’s of the old and new
AEDs separately. This graph reveals that the prevalence of
the new AEDs was significantly lower than that of the old
AEDs, that between 1997 and 2003 there was no significant
difference between the prevalence of old AEDs and the
overall prevalence and that for both groups of AEDs there
were no significant differences between successive years
and no significant trends.
Utilization of individual AEDs
As shown in Fig. 2, the AED with the highest prevalence
was valproic acid, followed by carbamazepine and lamo-
trigine. The prevalence of valproic acid was constant during
all years, while that of carbamazepine and lamotrigine
increased slightly; however, there were no significant
differences between successive years, and both trends were
not significant. In 1997, vigabatrin had a higher prevalence
than lamotrigine, but during the following years the
prevalence dropped rapidly, although there were no
significant differences between successive years and no
significant trend. The prevalence of phenobarbital was
constant at around 0.25 per 1000 children. Levetiracetam
was introduced on the Dutch market in 2000, and its
prevalence increased (although not significant) from 0.04 in
2001 to 0.29 in 2005. For other AEDs, prevalences were
around 0.2 per 1000 children or lower (data not shown).
Combination therapy
The study population accounted for a total of 19,829
person-months of AED use during the whole study period
(1997–2005). In 20.3% of these months, two or more AEDs
were prescribed, with a maximum of four AEDs per
person-month. A total of 239 children (22.8%) were
prescribed two or more AEDs for at least one person-
month, and only nine children (0.9%) were prescribed four
AEDs in 1 month.
The number of person-months in which two or more
AEDs were prescribed varied from 1 to 103, with 34.2% of
the children receiving combination therapy for 3 person-
months or less.
In 2000–2005, which is the period that most of the new
AEDs were on the Dutch market, therapy with an AED was
given in 15,303 person-months. Figure 3 shows the
percentages of person-months for every AED in which it
was given as monotherapy or in combination therapy.
Valproic acid was the most highly prescribed AED in both
mono- and combination therapy (51.5 and 14.7%, respec-
tively), followed by carbamazepine in monotherapy
(15.2%) and lamotrigine in combination therapy (12.4%
of all person-months vs. 7.7% for carbamazepine). Valproic
acid, carbamazepine and the other old AEDs (phenobarbi-
tal, phenytoin and ethosuximide) were prescribed more
often in monotherapy than in combination therapy, while
the opposite was true for lamotrigine and other new AEDs
(higher prescribing percentages in combination than in
monotherapy.
Duration of use
A total of 812 patients could be used for survival analyses
(analyses of the duration of AED use). Their overall
discontinuation of treatment is shown in Fig. 4a, and has
a median of approximately 2 years. Figure 4b shows the
discontinuation of treatment for boys (48.6%) and girls




During the period 1997–2005 the average year-prevalence
of AED-prescribing in Dutch children aged 0–19 years was
4.0 per 1000 children and the cumulative incidence was
0.67 per 1000 children per year. Valproic acid was the most
frequently prescribed AED, followed by carbamazepine and
lamotrigine. The older AEDs were prescribed more as
monotherapy than combination therapy, while the opposite
Table 2 Number and cumulative incidence per 1000 children (aged
0–19 years) per year
Year n Incidence 95% Confidence
interval
1997 95,158 0.57 0.43 – 0.75
1998 103,591 0.56 0.43 – 0.73
1999 110,229 0.72 0.57 – 0.90
2000 110,943 0.70 0.56 – 0.88
2001 112,131 0.59 0.46 – 0.75
2002 114,598 0.72 0.57 – 0.89
2003 116,649 0.70 0.56 – 0.88
2004 118,415 0.74 0.60 – 0.92
2005 119,612 0.77 0.62 – 0.95
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was true for the new AEDs. The prescribing of AEDs
during the study period seems to be in conformity with the
overall recommendations of the guidelines on treatment of
epilepsy in children.
The 50% survival probability of children to whom AEDs
are prescribed is around 2 years. This is in conformity with
the guidelines, for they advise that treatment with an AED
should be discontinued when a child is seizure-free for 1–
2 years.
Strengths and weaknesses
This study was conducted with data from the IADB.nl,
which is a prescription dispensing database; consequently,
there was no information on the actual use of the dispensed
medicines by the children. Therefore, one limitation to our
study is that we investigated dispensing rather than actual
drug use, with the assumption that dispensing data are
representative for the AEDs used in the population. The
strength of this database is that it contains data on a large
portion of the Dutch population for a large period of time
and that dispensing records are gathered prospectively.
Another limitation is that the actual indication for which
AEDs were prescribed was not actually known, but
estimated from other drugs prescribed. As such, the
estimation is only a rough one, but there was no other
possibility to classify the indication.
The IADB.nl does not contain information on the use of
OTC medication, but this did not represent a limitation for
this study, since in the Netherlands none of the AEDs is
available as an OTC. The IADB.nl also does not contain
prescriptions prescribed during hospitalization, but as the
majority of children are prescribed AEDs in an outpatient
setting, this will have no effect on the results.
The number of patients included in this study was small
due to the low cumulative incidence and prevalence. This
limited our results since survival analyses could not be
performed for most individual AEDs because there were 30























all AEDs old AEDs new AEDs
Fig. 1 Prevalences per 1000
children (aged 0–19 years) of



















phenobarbital vigabatrin valproic acid
Fig. 2 Prevalences per
1000 children (aged 0–19 years)
of carbamazepine, lamotrigine,
levetiracetam, phenobarbital,
valproic acid and vigabatrin
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The use of person-months to investigate combination
therapy is a helpful approach to obtain insight in how often
combination therapy is prescribed. The drawback of
counting person-months is that when a patient is prescribed
two AEDs consecutively, the number of AEDs counted in 1
person-month is two, even though these AEDs are not used
together. Thus, the percentages of combination therapy are
probably overestimated in this study. On the other hand, the
guidelines recommend that, when there is a change in
AEDs, the patient should not switch medication abruptly
from one day to the other but that both AEDs should be
used during a transition period [2, 4, 5]. To prevent this
overestimation, one could use person-days, but this ap-
proach generates too much data to handle. Therefore, we
accept the possibility of an overestimation due to the use of
person-months, but assume that it is small and that person-
months are a useful tool in analysing combination therapy.
Results compared to those reported in the literature
The prevalences and cumulative incidences that we found
correspond with prevalences and incidences reported on the
prescription of AEDs to children in Denmark, where the
average prevalence for children 5–14 years old is approx-
imately 5 per 1000 person-years [11], and the average
incidence for children <16 years is around 0.5 per 1000
person-years [12]. In the USA, the prevalence was reported
to be 17.5 per 1000 children in 2000 [13]. This prevalence
is remarkably higher than those in the Netherlands and
Denmark, probably because in the USA AEDs are
prescribed for psychiatric disorders (68%) more often than
in the Netherlands (10% [13]) and Denmark (18% [12]).
A recent study using data on children aged 0–18 years
from 1997–2005 that were extracted from the General
Practice Research Database (GPRD) of the UK reported a
prevalence of AEDs of approximately 8 per 1000 person-
years and an average incidence of around 0.7 per 1000
person-years [14]. Thus, the incidence in the UK is similar
to that reported for the Netherlands, but the prevalence is
higher, suggesting that in the UK, children are treated for a
longer period of time than in Denmark and the Netherlands.
Our study shows that in the Netherlands, children who
receive their first AED prescription have a 50% survival
probability of around 2 years. To our knowledge, this
survival probability is not known for children in the UK
who receive one or more AED prescriptions; therefore, this
hypothesis can not be tested.
The prevalences of individual AEDs, as shown in Fig. 2,
are in conformity with the guidelines that recommend
valproic acid as the AED of first choice for most seizure
types and epileptic syndromes [2, 4, 5]. Carbamazepine is
also effective in many seizure types, but may worsen others
and is therefore, not advised as often as valproic acid [2, 4,
5]. Consequently, it has the second highest prevalence.
Lamotrigine also has a broad antiepileptic spectrum and
fewer side-effects than valproic acid and carbamazepine.
However, because physicians have less experience with the
prescribing of these newer AEDs and because they are
more expensive [15], lamotrigine is advised as a second-
choice AED [4, 5]; therefore, it has a lower prevalence than
valproic acid and carbamazepine. Of the new AEDs,
lamotrigine is prescribed the most, which is in agreement
with data from the UK [14] and Denmark [11]. The
decrease in the prevalence of vigabatrin after 1997, also
mentioned by Ackers et al., is probably the result of reports
that vigabatrin can cause irreversible visual field defects
[16]. The prevalence of phenobarbital is constant and
higher than that of the new AEDs, even though this old
AED has more severe side-effects than the new AEDs [17].
It has also been prescribed mostly to the youngest age
category (0–4 years), likely due to its unique position of
being recommended for the treatment of neonatal seizures



















Fig. 3 Proportions of person-
months in which children were
treated with an AED in mono-
or combination therapy, per
AED (n=15303 person-months)
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[5, 18]. Levetiracetam has on the Dutch market for a few
years, and the increase in prevalence indicates its popularity
among prescribers.
In our study, valproic acid and carbamazepine were the
most prescribed AEDs in monotherapy in terms of person-
months. This result is in conformity with the overall
recommendations of the guidelines that recommend that
monotherapy is the preferred treatment over combination
therapy, with valproic acid and carbamazepine being the
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Fig. 4 a Overall Kaplan-Meier
curve, with 95% confidence in-
terval. b Kaplan–Meier curve
per sex. Solid black Boys,
dashed grey girls
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agreement with the guidelines—that new AEDs should be
used as add-on therapy to an old AED—are the higher
percentages we found for the new AEDs in combination
therapy than in monotherapy[2, 4, 5]. The percentages of
pregabalin in our study were close to zero due to its
approval only in July 2004; consequently, it was on the
Dutch market for only 5 months of the total study period of
108 months.
Our finding that 70% of the children discontinue
treatment after 9 years is in agreement with the finding
that 64% of the Dutch children discontinue treatment after
5 years [19]. The reason for the significant difference in the
discontinuation of treatment of boys and girls is not known,
but it may possibly be due to a re-consideration in the
prescribing of an AED when girls start using contraceptives
since many AEDs interact with oral contraceptives [20].
Conclusion
The results of this study show that valproic acid, carbama-
zepine and lamotrigine were the mostly frequently pre-
scribed AEDs for children aged 0–19 years between 1997
and 2005. This prevalence is in conformity with the overall
recommendations of the guidelines for the treatment of
epilepsy in children. After 2 years, the medication was
stopped in 50% of all children who were prescribed an
AED. In combination therapy older AEDs are combined
with newer AEDs, but valproic acid is still the most highly
prescribed AED.
To our knowledge, this is the first study that has
analysed the prescribing AEDs in combination therapy
and the duration of their use.
Open Access This article is distributed under the terms of the
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